Description
A glycoside with diverse biological activities; induces cell cycle arrest at the G0/G1 phase, decreases cyclin A and Cdk2 levels, and inhibits cell growth in UMUC-3, RT112, and TCCSUP bladder cancer cells from 1.25-10 mg/ml; reduces the number of primary microtubules and microvessels in aortic rings isolated from rats with streptozotocin-induced diabetes at 3 mg/kg; reduces triglyceride, total cholesterol, and LDL levels and aortic sinus plaque area in an LDLR-/- mouse model of atherosclerosis; reduces production of TNF-α, IL-1β, and IL-6 as well as neutrophil and macrophage infiltration in BALF in a mouse model of LPS-induced acute lung injury
Formal name: αR-[(6-O-β-D-glucopyranosyl-β-D-glucopyranosyl)oxy]-benzeneacetonitrile
Synonyms: (–)-Amygdalin|(D)-Amygdalin|(R)-Amygdalin|Amygdaloside|NSC 15780
Molecular weight: 457.4
CAS: 29883-15-6
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Natural Products|Glycosides||Research Area|Cancer|Cell Cycle|G1||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Diabetes||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Dyslipidemias||Research Area|Immunology & Inflammation|Innate Immunity||Research Area|Immunology & Inflammation|Pulmonary Diseases